View Exam | PowerPak

1. A 58-year-old African American woman with type 2 diabetes has purchased a package of absorbency pads at her community pharmacy. She lives with and is caring for her elderly mother. Which of the following aspects of her profile would LEAST likely prompt you to inquire about OAB symptoms?

A. Her age B. Her ethnicity C. Presence of diabetes D. Purchase of absorbency pads

2. Amy is a 62-year-old woman who was prescribed oxybutynin extended release (ER) 5 mg daily for her symptoms of OAB. She reports significant improvement in her feelings of urgency and some improvement in frequency, although she still feels “obsessed with always knowing where the closest bathroom is.” She also does not care for the dry mouth she is experiencing and is wondering whether she will have to take this medication for the rest of her life. Which of the following would be the BEST therapeutic option in managing her OAB?

A. Increase the dose to 10-mg oxybutynin ER and take it with a full glass of water B. Switch to a β₃ adrenergic receptor (AR) agonist C. Discontinue oxybutynin and initiate neuromodulation D. Discontinue oxybutynin and initiate onabotulinum toxin treatment

3. Which of the following statements regarding vibegron is FALSE?

A. The most frequent adverse event is dry mouth. B. The tablets can be crushed. C. Titration is not required. D. It is not recommended in individuals with renal or severe hepatic impairment.

4. Which of the following medications DOES NOT contribute to OAB symptoms?

A. Estradiol B. Metoprolol C. Hydrochlorothiazide D. Lorazepam

5. Which β₃ AR agonist is associated with slight elevations in blood pressure and heart rate, is approved for use in combination with solifenacin, and is currently available in an ER formulation?

A. There are no β₃ AR agonists available as ER formulations B. Mirabegron C. Solabegron D. Vibegron

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A 58-year-old African American woman with type 2 diabetes has purchased a package of absorbency pads at her community pharmacy. She lives with and is caring for her elderly mother. Which of the following aspects of her profile would LEAST likely prompt you to inquire about OAB symptoms?

3. Which of the following statements regarding vibegron is FALSE?

4. Which of the following medications DOES NOT contribute to OAB symptoms?

5. Which β₃ AR agonist is associated with slight elevations in blood pressure and heart rate, is approved for use in combination with solifenacin, and is currently available in an ER formulation?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. A 58-year-old African American woman with type 2 diabetes has purchased a package of absorbency pads at her community pharmacy. She lives with and is caring for her elderly mother. Which of the following aspects of her profile would LEAST likely prompt you to inquire about OAB symptoms?

3. Which of the following statements regarding vibegron is FALSE?

4. Which of the following medications DOES NOT contribute to OAB symptoms?

5. Which β3 AR agonist is associated with slight elevations in blood pressure and heart rate, is approved for use in combination with solifenacin, and is currently available in an ER formulation?

« Return to Activity

Customers who Purchased
this Activity also Purchased

5. Which β₃ AR agonist is associated with slight elevations in blood pressure and heart rate, is approved for use in combination with solifenacin, and is currently available in an ER formulation?